Video

Dr. Ghodoussipour on Ongoing Trials in Non–Muscle Invasive Bladder Cancer

Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer.

Saum Ghodoussipour, MD, urologic oncologist, director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute of New Jersey, assistant professor of surgery, Rutgers Robert Wood Johnson Medical School, attending, Robert Wood Johnson University Hospital, discusses ongoing trials in non–muscle invasive bladder cancer (NMIBC).

Several interesting studies are taking place currently in NMIBC, which is how most patients with bladder cancer present, Ghodoussipour says. The standard of care currently is intravesical therapy with Bacillus Calmette-Guérin (BCG), the vaccine for tuberculosis, Ghodoussipour adds. The therapy stimulates a local immune response in this patient population; however, almost half of patients do not derive a response resulting in the need for additional invasive treatments, Ghodoussipour explains.

Clinicians are studying BCG in combination with the checkpoint inhibitor pembrolizumab (Keytruda), with the goal of improving treatment after prior failure with BCG, Ghodoussipour continues. Moreover, clinicians are attempting to give BCG and pembrolizumab in the frontline setting for patients with treatment-naïve NMIBC to see whether it will improve outcomes for patients, Ghodoussipour concludes.

Related Videos
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS
Rona Yaeger, MD
 PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Robert
Charles B. Nguyen, MD
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC